Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "BioPharma-Reporter" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about BioPharma-Reporter for you to read. Along with our medical data and news we also list BioPharma-Reporter Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharma-Reporter Companies for you to search.
The US FDA is faced with lapsed funding appropriations as the US government shutdown continues, causing the agency to focus on addressing immediate threats to consumer safety.
The UK company will close two facilities in Boulder and Longmont eliminating 210 positions.
Sarepta signed a long-term agreement for the supply of plasmid DNA for its gene therapy program and the needs of any future programs.
DuPont has developed an excipient that could be more efficient and stable than current products on the market.
Biosimilar approvals in the US have increased by 600% and with biologic patent expiration dates approaching, biosimilar applications are on the rise as well.
Catalent will use the funds to enlarge drug substance manufacturing and drug product fill/finish capacity.
Takeda entered multiple research collaborations for immuno-oncology and CAR-T therapies, an area of strategic focus for the company.
Novartis treatment for migraines is rejected by NICE on cost-effectiveness grounds, and on a lack of long-term data.
BMS' CEO explains that the deal will help the company to âparticipate in the growth and evolutionâ of oncology, spearheaded by cellular therapies.
Cabaletta Bio closed a $50m Series B funding enabling the company to develop further in the CAAR-T space.
Janssen has licensed Locusâ CRISPR-Cas3 technology to target two bacterial pathogens for the development of treatments for infections.
Fujifilm has launched an upgrade to its subsidiaries manufacturing capabilities, by increasing capacity by 50% at an existing facility and building an entirely new site for cell technology.
Sanofi and Regeneron updated their 2015 global immune-oncology discovery and development agreement to refocus drug discovery.
Sanofi and Regeneron updated their 2015 global immune-oncology Discovery and Development Agreement to refocus drug discovery and give Sanofi more flexibility in advancing a pipeline.
2018 saw an increase in the number of biosimilar approvals, and the expiry of patents on major products that allowed the entry of biosimilars across Europe.
Harpoon offers to sell shares of its common stock in its proposed IPO after registering a statement with the SEC while developing T-Cell engagers.
Eli Lilly and Innovent announced that their jointly developed anti-PD-1 drug gained approval in China, becoming the second domestically produced treatment of this type.
With nearly 300 cell and gene therapies in development, targeting more than 100 diseases, 2019 could be set to be a big year for cell and gene therapies.
HJB and MabSpace merge, combining drug development, commercialization, and GMP manufacturing capabilities, to establish Transcenta.
Novartis will acquire French CDMO, CellforCure, to expand its cell and gene therapy manufacturing network.
Rentschler Biopharma will buy Shireâs development and manufacturing facility in Milton, Massachusetts, where the latter makes haemophilia A product, Obizur, for commercial production.
genOway has acquired exclusive rights to MilliporeSigma's genome-editing patents to produce and sell new rodent models.
Alnylam settled its patent litigation with Silence Therapeutics, after an ongoing litigation regarding patent infringement of Silenceâs RNAi therapy.
Transformation in cell therapies is happening at an even faster rate than the US, suggests Christoph Heinemann of Sanofi.
The EMA has recommended approval of Pfizerâs Zirabev, a proposed biosimilar to Rocheâs Avastin.